Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/19248
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKalogirou, M.en
dc.contributor.authorTsimihodimos, V.en
dc.contributor.authorElisaf, M. S.en
dc.date.accessioned2015-11-24T18:58:07Z-
dc.date.available2015-11-24T18:58:07Z-
dc.identifier.issn1879-0712-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/19248-
dc.rightsDefault Licence-
dc.subjectAnimalsen
dc.subjectAnticholesteremic Agents/pharmacology/therapeutic useen
dc.subjectAtherosclerosis/*drug therapyen
dc.subjectAzetidines/*pharmacology/*therapeutic useen
dc.subjectBiological Markers/metabolismen
dc.subjectDisease Models, Animalen
dc.subjectEndothelium, Vascular/drug effectsen
dc.subjectHumansen
dc.subjectInflammation/*drug therapy/metabolismen
dc.subjectInflammation Mediatorsen
dc.subjectLipid Metabolism/*drug effectsen
dc.subjectPlatelet Aggregation/drug effectsen
dc.subjectTreatment Outcomeen
dc.titlePleiotropic effects of ezetimibe: do they really exist?en
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1016/j.ejphar.2010.02.003-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/20152830-
heal.identifier.secondaryhttp://ac.els-cdn.com/S0014299910000865/1-s2.0-S0014299910000865-main.pdf?_tid=66ea5c63c740e7b39c359383c65d1fa6&acdnat=1334038252_e71473eeda77cb3702f5ce4df8928a5e-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2010-
heal.abstractEzetimibe represents a new lipid lowering agent which inhibits cholesterol absorption. It effectively reduces low-density lipoprotein cholesterol when administered either alone or in combination with statins. However, its effect on cardiovascular mortality remains under question since it failed to demonstrate any significant changes in the primary endpoints of the recently published ENHANCE and SEAS studies. A possible explanation for this unsuccessful outcome is that ezetimibe lacks pleiotropic effects. This article aims to review the potential pleiotropic effects of the drug mainly on inflammation markers, lipoprotein subfractions and endothelial function.en
heal.journalNameEuropean Journal of Pharmacologyen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
File Description SizeFormat 
Kalogirou-2010-Pleiotropic effects.pdf229.39 kBAdobe PDFView/Open    Request a copy


This item is licensed under a Creative Commons License Creative Commons